Grünenthal acquires full ownership of Grünenthal Meds from Kyowa Kirin

Grünenthal acquired Kyowa Kirin International's 49% stake in Grünenthal Meds, taking full ownership of the joint venture and its portfolio of 12 established medicine brands with €170 million in revenue.

“The integration of 'Grünenthal Meds' confirms our leading capabilities in deal execution and integration and successfully concludes one of the most complex undertakings of our M&A journey.”americanpharmaceuticalreview.com

• 1 source
• americanpharmaceuticalreview.comGrünenthal Takes Full Ownership of Grünenthal Meds, the JV Established with Kyowa Kirin for its Medicine Brands | American Pharmaceutical Review - The Review of American Pharmaceutical Business & TechnologyMar 2, 2026

Summarized from public sources; check the original articles before acting on it.